1 / 18

TSSG

TSSG. Thida Win 13 th May 2013. Recommendations (England).

trilby
Download Presentation

TSSG

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TSSG Thida Win 13th May 2013

  2. Recommendations (England) 1. All hospitals trusts and health boards should participate in this national audit, should submit data on all patients presenting to secondary care diagnosed with either lung cancer or mesothelioma, and should complete all relevant data fields for each individual patient. 2. Data completeness for key fields should exceed 85 per cent and for MDT completeness should exceed 95 per cent (See appendix 2 Local Action Plan). 3. Data completeness for the co-morbidity field should exceed 85 per cent, and for patients with Stage I-II and PS0-1, completeness for FEV1 and FEV1% should exceed 75 per cent. 4. Maintain the level of 95 per cent of patients submitted to the audit being discussed at a Multidisciplinary Team Meeting.

  3. 5.Histological/Cytological confirmation rates below 75 per cent should be reviewed to determine whether best practice is being followed and whether patients have access to the whole range of biopsy techniques. 6. Non Small Cell Lung Cancer, not otherwise specified (NSCLC NOS) rate of more than 20 per cent should be reviewed to ensure that best practice histological diagnostic techniques including immunohistochemistry are being followed, in order that patients receive appropriate chemotherapy regimens. 7. At least 80 per cent of patients are seen by a lung cancer specialist nurse; at least 80 per cent of patients should have a lung cancer specialist nurse present at the time of diagnosis (note that these data are not available for Wales). 8. For patients undergoing bronchoscopy at least 95 percent should have a CT scan prior to the procedure.

  4. 9. Surgical resection rates for NSCLC below the England and Wales average of 14 per cent should be reviewed. Furthermore for early stage (I and II) disease, rates below 52 per cent should be reviewed to ensure that patient on the margins of operability/resectability are being offered access to specialist thoracic surgical expertise (including second opinions). 10. Active anti-cancer treatment rates below the England and Wales average of 60 per cent should be reviewed. 11. Chemotherapy rates for small cell lung cancer below the England and Wales average of 65 per cent should be reviewed. 12. Chemotherapy rates for good performance status (0-1) stage IIIB / IV NSCLC lung cancer below the England and Wales average of 55 per cent should be reviewed.

  5. N20 Mount Vernon Cancer Network • RC9 Luton and Dunstable Hospital NHS Foundation Trust • RWG West Hertfordshire Hospitals NHS Trust • RWH East and North Hertfordshire NHS Trust

  6. Report for the audit period 2011 Percentage of patients receiving a histological / cytological diagnosis • England and Wales • 2011 2010 2009 • 33,463 32,347 32,068 • 76.9 76.0 75.6 • N20 79.1, RC9 78.0, RWG 79.7, RWH 79.7 • Histological/Cytological confirmation rates below 75 per cent should be reviewed to determine whether best practice is being followed and whether patients have access to the whole range of biopsy techniques.

  7. Percentage of patients receiving an operation England and Wales • 2011 2010 2009 • 33,463 32,347 32,068 • 14.7 13.7 13.7 • Surgical resection rates for NSCLC below average of 14% should be reviewed. Furthermore for early stage (I and II) disease, rates below (52%) should be reviewed. N20 15.1(43.4), RC9 24.2 (54.5), RWG 7.0 (6.7), RWH 14.4 (51.3)

  8. Percentage of patients receiving any anti cancer treatment • England and Wales • 2011 2010 2009 • 33,463 32,347 32,068 • 60.1 58.4 59.1 • Active anti-cancer treatment rates below the England and Wales average of 60 per cent should be reviewed. • N20 53.6, RC9 45.7, RWG 55.1, RWH 59.4

  9. At least 80 per cent of patients are seen by a lung cancer specialist nurse • N20 82.1, RC9 67.7, RWG 93.0, RWH 85.0 • at least 80 per cent of patients should have a lung cancer specialist nurse present at the time of diagnosis • N20 65.2, RC9 60.8, RWG 62.0, RWH 72.3 • Chemotherapy rates for small cell lung cancer below the England and Wales average of 65 per cent should be reviewed • N20 62.9%, RC9 42.9%, RWG 66.7%, RWH 70.8%

  10. Radiotherapy • N20 20.0 • RC9 15.6 • RWG 18.2 • RWH 25.7 • LUCADA 29.2

  11. Date first seen = 2012 (all). Date of extract = 02/04/2013

  12. Data Completeness

  13. Data completeness

  14. Clinical measures

  15. Action Plan • Continue data collection • Proactive for active treatment • Find way to increase nurse present at the time of diagnosis • Improve pathological sub classification for NSCLC from NOS • Improve surgical rates • Others?

  16. Thank You

More Related